Amy Pierre, ANP-BC, on Multiple Myeloma: CANDOR Trial of Carfilzomib, Dexamethasone, and Daratumumab

Amy Pierre, ANP-BC, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings that suggest the combination of carfilzomib, dexamethasone, and daratumumab represents an efficacious new regimen for patients with relapsed or refractory disease, including those who are refractory to lenalidomide (Abstract LBA-6).